FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

By M. Cohen, Grant A. Williams, R. Sridhara, Gang Chen, R. Pazdur. The Oncologist, 2003

608 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3e472c846b8b0fa5c19df49967b3b42852da6744

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. William Pao
2. Vincent A. Miller
3. M. Kris
4. Piotr Fryzlewicz

In Oncology

1. William Pao
2. Vincent A. Miller
3. M. Kris

In Pulmonary and Respiratory Medicine

1. William Pao
2. Vincent A. Miller
3. M. Kris
4. Gregory Riely
5. Adi F. Gazdar

Citations in the corpus

• Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. (2004, result): “However, a recent review of subgroups of patients treated on IDEAL 2 revealed strikingly similar results to those reported here [18].”